A Phase 4 interventional study of Voriconazole in Candidiasis, Cryptococcosis and Aspergillosis, sponsored by Pfizer. Completed at 4 sites in Taiwan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-05-16.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Candidiasis by Pfizer — none open to participants now, none under way, none of them phase 3. Candidiasis · Pfizer.
Among the 15 studies in Candidiasis by Pfizer, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2003, is one of 2 in phase 4, and was the 9th registered.
132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.
Browse Candidiasis studies →None of the 15 studies in Candidiasis by Pfizer is open now. The open studies under Candidiasis, anywhere →
Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 91 across 86 interventional studies indexed under Candidiasis.
Median enrollment 41 across the 11 interventional studies, 526 across the 2 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Candidiasis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Voriconazole
Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
Serological response (evaluated by approved diagnostic serological tests [cryptococcosis, coccidiomycosis, and histoplasmosis]) at Weeks 2, 8, 12, and end of therapy.
Time frame: Weeks 2, 8, 12, and end of therapy
Clinical response (evaluated based on change of attributable symptoms, signs, and/or bronchoscopic abnormalities present at baseline, judged by investigators, at Weeks 1, 2, 4, 8, 12, and end of therapy) at Weeks 1, 2, 4, 8, 12, and end of therapy.
Time frame: Weeks 1, 2, 4, 8, 12 and end of therapy
Radiological response (evaluated based on all radiological abnormalities [X-ray, computed tomography scan] attributed to fungal infection compared to baseline) at Weeks 2, 8, 12, and end of therapy.
Time frame: Weeks 2, 8, 12, and end of therapy
Mycological response (evaluated by the presences of fungal pathogen by relevant specimen [microscopy or histopathology]) at Weeks 2, 8, 12, and end of therapy.
Time frame: Weeks 2, 8, 12, and end of therapy
Global response to treatment (incorporating clinical, mycological, radiological, and serological responses as applicable) at end of therapy/Week 16.
Time frame: End of therapy or Week 16
Change from baseline in laboratory parameters at Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up.
Time frame: Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up
Change from baseline in electrocardiogram at Week 1 and end of therapy.
Time frame: Week 1 and end of therapy
Incidence of adverse events at Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up.
Time frame: Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up
Visual safety testing at Weeks 1, 8, 12, end of therapy, Week 16, and follow-up.
Time frame: Weeks 1, 8, 12, end of therapy, Week 16, and follow-up
The record gives a start of Apr 2003 and a completion of May 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole